Expression Patterns of Angiopoietin-1,-2, and Tie-2 Receptor in Ulcerative Colitis Support Involvement of the Angiopoietin/Tie Pathway in the Progression of Ulcerative Colitis

被引:11
作者
Yoshizaki, Ayumi [1 ]
Nakayama, Toshiyuki [1 ]
Naito, Shinji [2 ]
Sekine, Ichiro [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Tumor & Diagnost Pathol, Nagasaki 8528523, Japan
[2] Natl Ureshino Med Ctr, Div Pathol, Res Lab, Saga, Japan
关键词
Ulcerative colitis; Crypt abscess; Immunohistochemistry; Angiopoietin; Tie; INFLAMMATORY-BOWEL-DISEASE; NECROSIS-FACTOR-ALPHA; QUALITY-OF-LIFE; TYROSINE KINASE; 5-AMINOSALICYLIC ACID; ENDOTHELIAL-CELLS; ADHESION MOLECULES; KAPPA-B; ANGIOGENESIS; THERAPY;
D O I
10.1007/s10620-008-0593-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
The active stage of ulcerative colitis (UC) involves transmigration of polymorphonuclear (PMN) cells to colonic epithelia. The angiopoietin (Ang) pathway plays a role as the regulator of PMN transmigration. To clarify the role of the Ang/Tie pathway in the activation of UC, especially in cypt abscess formation, 67 tissue samples were obtained from patients with UC and ten controls without UC for immunohistochemical analysis for the expression of Ang-1, -2, or Tie-2. The epithelia of crypt abscess was strongly positive for Ang-1 and -2 for all 57 samples derived from patients with active UC, though the colorectal epithelium without crypt abscess showed minimal expression of Ang-1, -2, and Tie-2. Numerous transepithelial migrating PMN cells in crypt abscesses also expressed Tie-2. The specimens of UC patients in remission showed significantly less immunoreactivity for Ang-1, -2, or Tie-2. These findings suggest that the Ang/Tie pathway may play a role in the progression of UC.
引用
收藏
页码:2094 / 2099
页数:6
相关论文
共 44 条
[1]
Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease [J].
Barrie, Arthur ;
Regueiro, Miguel .
INFLAMMATORY BOWEL DISEASES, 2007, 13 (11) :1424-1429
[2]
BEMATCHEZ PN, 1999, J BIOL CHEM, V274, P31047, DOI DOI 10.1074/JBC.274.43.31047
[3]
TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION [J].
BRAEGGER, CP ;
NICHOLLS, S ;
MURCH, SH ;
STEPHENS, S ;
MACDONALD, TT .
LANCET, 1992, 339 (8785) :89-91
[4]
Impairment of health-related quality of life in patients with inflammatory bowel disease:: A Spanish multicenter study [J].
Casellas, F ;
Arenas, JI ;
Baudet, JS ;
Fábregas, S ;
García, N ;
Gelabert, J ;
Medina, C ;
Ochotorena, I ;
Papo, M ;
Rodrigo, L ;
Malagelada, JR .
INFLAMMATORY BOWEL DISEASES, 2005, 11 (05) :488-496
[5]
Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J].
Davis, S ;
Aldrich, TH ;
Jones, PF ;
Acheson, A ;
Compton, DL ;
Jain, V ;
Ryan, TE ;
Bruno, J ;
Radziejewski, C ;
Maisonpierre, PC ;
Yancopoulos, GD .
CELL, 1996, 87 (07) :1161-1169
[6]
DOMINANT-NEGATIVE AND TARGETED NULL MUTATIONS IN THE ENDOTHELIAL RECEPTOR TYROSINE KINASE, TEK, REVEAL A CRITICAL ROLE IN VASCULOGENESIS OF THE EMBRYO [J].
DUMONT, DJ ;
GRADWOHL, G ;
FONG, GH ;
PURI, MC ;
GERTSENSTEIN, M ;
AUERBACH, A ;
BREITMAN, ML .
GENES & DEVELOPMENT, 1994, 8 (16) :1897-1909
[7]
Inhibition of interleukin-1-stimulated NF-kappa B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity [J].
Egan, LJ ;
Mays, DC ;
Huntoon, CJ ;
Bell, MP ;
Pike, MG ;
Sandborn, WJ ;
Lipsky, JJ ;
McKean, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (37) :26448-26453
[8]
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study [J].
Faubion, WA ;
Loftus, EV ;
Harmsen, WS ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2001, 121 (02) :255-260
[9]
Fenoglio-Preiser C.M., 1999, GASTROINTESTINAL PAT
[10]
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review [J].
Fraser, AG ;
Orchard, TR ;
Jewell, DP .
GUT, 2002, 50 (04) :485-489